Cao, Shaolong
Wang, Jennifer R.
Ji, Shuangxi
Yang, Peng http://orcid.org/0000-0002-0630-9506
Dai, Yaoyi
Guo, Shuai
Montierth, Matthew D. http://orcid.org/0000-0002-0860-1420
Shen, John Paul
Zhao, Xiao
Chen, Jingxiao
Lee, Jaewon James
Guerrero, Paola A.
Spetsieris, Nicholas
Engedal, Nikolai http://orcid.org/0000-0003-3718-3464
Taavitsainen, Sinja http://orcid.org/0000-0001-7559-9853
Yu, Kaixian
Livingstone, Julie http://orcid.org/0000-0002-8424-3768
Bhandari, Vinayak http://orcid.org/0000-0003-0265-0835
Hubert, Shawna M. http://orcid.org/0000-0002-7907-9609
Daw, Najat C. http://orcid.org/0000-0002-6941-8005
Futreal, P. Andrew http://orcid.org/0000-0001-8663-2671
Efstathiou, Eleni
Lim, Bora http://orcid.org/0000-0002-4182-6058
Viale, Andrea
Zhang, Jianjun http://orcid.org/0000-0001-7872-3477
Nykter, Matti http://orcid.org/0000-0001-6956-2843
Czerniak, Bogdan A.
Brown, Powel H. http://orcid.org/0000-0002-3398-163X
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Msaouel, Pavlos
Maitra, Anirban http://orcid.org/0000-0001-7923-9978
Kopetz, Scott http://orcid.org/0000-0001-9647-3416
Campbell, Peter http://orcid.org/0000-0002-3921-0510
Speed, Terence P. http://orcid.org/0000-0002-5403-7998
Boutros, Paul C. http://orcid.org/0000-0003-0553-7520
Zhu, Hongtu http://orcid.org/0000-0002-6781-2690
Urbanucci, Alfonso
Demeulemeester, Jonas
Van Loo, Peter http://orcid.org/0000-0003-0292-1949
Wang, Wenyi http://orcid.org/0000-0003-0617-9438
Article History
Received: 7 June 2021
Accepted: 29 April 2022
First Online: 13 June 2022
Competing interests
: A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology. A.M. is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. A.M. is a consultant for Freenome and Tezcat Biotechnology. J.Z. reports research funding from Merck and Johnson & Johnson and consultant fees from Bristol Myers Squibb (BMS), Johnson & Johnson, AstraZeneca, Geneplus, OrigMed and Innovent outside of the submitted work. P.M. has received honoraria for service on a Scientific Advisory Board for Mirati Therapeutics and BMS, non-branded educational programs supported by Exelixis and Pfizer and research funding for clinical trials from Takeda, BMS, Mirati Therapeutics and Gateway for Cancer Research. W.W. reports research funding from Curis, Inc. J.P.S. and W.W. report research funding from Celsius Therapeutics. J.P.S. is a paid consultant for Engine Biosciences. S.K. has ownership interest in MolecularMatch, Lutris and Iylon and is a consultant for Genentech, EMD Serono, Merck, Holy Stone, Novartis, Eli Lilly, Boehringer Ingelheim, Boston Biomedical, AstraZeneca/MedImmune, Bayer Health, Pierre Fabre, Redx Pharma, Ipsen, Daiichi Sankyo, Natera, HalioDx, Lutris, Jacobio, Pfizer, Repare Therapeutics, Inivata, GlaxoSmithKline, Jazz Pharmaceuticals, Iylon, Xilis, Abbvie, Amal Therapeutics, Gilead Sciences, Mirati Therapeutics, Flame Biosciences, Servier, Carina Biotechnology, Bicara Therapeutics, Endeavor BioMedicines, Numab Pharma and Johnson & Johnson/Janssen and receive research funding from Sanofi, Biocartis, Guardant Health, Array BioPharma, Genentech/Roche, EMD Serono, MedImmune, Novartis, Amgen, Eli Lilly and Daiichi Sankyo. P.A.F. reports research funding from MEI Pharma, Inc. P.H.B. owns stock in GeneTex. C.S. acknowledges grant support from AstraZeneca, Boehringer Ingelheim, BMS, Pfizer, Roche-Ventana, Invitae (previously Archer Dx—collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical. C.S. is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also chief investigator of the NHS Galleri trial. C.S. has consulted for Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, Merck, BMS, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Metabomed, Bicycle Therapeutics, Roche Innovation Centre Shanghai and the Sarah Cannon Research Institute. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021; currently has stock options in Epic Bioscience and Bicycle Therapeutics; and has stock options in and is a co-founder of Achilles Therapeutics. C.S. holds various patents relating to assay technology for cancer; US patents relating to detecting tumor mutations and methods for lung cancer detection; and both a European and a US patent related to identifying insertion/deletion mutation targets. All is outside the submitted work. The remaining authors declare no competing interests.